This work is licensed under a Creative Commons Attribution 4.0 International License.
CIGB-300 (P15-Tat)
General Information
DRACP ID DRACP00119
Peptide Name CIGB-300 (P15-Tat)
Sequence CWMSPRHLGTCGRKKRRQRRRPPQ
Sequence Length 24
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Transducing peptide Cell-penetrating peptides
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| TC-1 | Human renal cell carcinoma | Carcinoma | IC50=71±15 µmol/L | MTS assay | 72 h | 1 |
| NCI-H125 | Lung adenosquamous carcinoma | Carcinoma | IC50=36±9 µmol/L | MTS assay | 72 h | 1 |
| NCI-H82 | Lung small cell carcinoma; Small cell lung cancer | Carcinoma | IC50=20±3 µmol/L | MTS assay | 72 h | 1 |
| SiHa | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | Carcinoma | IC50=135±10 µmol/L | MTS assay | 72 h | 1 |
| Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | Carcinoma | IC50=182±6 µmol/L | MTS assay | 72 h | 1 |
| HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=136±16 µmol/L | MTS assay | 72 h | 1 |
| Jurkat | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | Leukemia | IC50=89±3 µmol/L | MTS assay | 72 h | 1 |
| HL-60 | Adult acute myeloid leukemia; Acute myeloid leukemia | Leukemia | IC50=30±3 µmol/L | MTT assay | 72 h | 2 |
| 3LL | Malignant tumors of the mouse pulmonary system | Carcinoma | IC50=143±4 µmol/L | MTT assay | 72 h | 2 |
| A549 | Lung adenocarcinoma | Carcinoma | IC50=171±12 µmol/L | MTT assay | 72 h | 2 |
| PC-3 | Prostate carcinoma | Carcinoma | IC50=201±16 µmol/L | MTT assay | 72 h | 2 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism CIGB-300 is a cyclic synthetic peptide that induces apoptosis in malignant cells, elicits antitumor activity in cancer animal models
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Cys1<--->Cys11
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C124H212N52O29S3
Absent amino acids ADEFINVY
Common amino acids R
Mass 340196
Pl 12.63
Basic residues 10
Acidic residues 0
Hydrophobic residues 2
Net charge 10
Boman Index -12321
Hydrophobicity -195
Aliphatic Index 16.25
Half Life
Mammalian: 1.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 5625
Absorbance 280nm 244.57
Polar residues 6
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 15466209
Title Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2)
Doi 10.1158/0008-5472.CAN-04-2086
Year 2004
Literature 2
Pubmed ID 24773585
Title Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines
Year 2014
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.